hc1 IQ™, an AI-powered intelligence platform unifying lab, clinical, and supply chain data into a single platform, has partnered with Protege, the platform for proprietary AI training and evaluation data, to make hc1’s extensive lab results dataset available through the Protege platform. This partnership introduces one of the most scalable and lab-centric datasets on the market, enabling AI developers to access rich, de-identified laboratory data across the United States to help close gaps in care, improve therapy adoptions and improve patient outcomes.

The dataset includes over 12 billion historical lab results, sourced from both reference labs and health system laboratories. It comprises lab order and result data, with primary coverage in structured formats, while also incorporating select unstructured components such as interpretive notes. Thanks to direct, real-time integration with lab systems, the data maintains a high level of fidelity and freshness.

All records are de-identified, allowing for easy connection to other modalities — including EMRs, claims, imaging, and omics — to create robust, multi-modal AI training datasets.

This lab-centric asset empowers development across key use cases including early disease detection, risk stratification, population health monitoring, diagnostics optimization, and precision medicine workflows.

“hc1 IQ™ brings an essential dimension to our platform: high-volume, high-integrity lab data that’s deeply embedded in clinical workflows,” said Bobby Samuels, CEO and Co-Founder of Protege. “This dataset enables developers to build models that understand disease progression, treatment response, and diagnostic patterns, all from the lab lens. It’s a crucial component for AI teams working on everything from early detection to chronic disease management.”

“We’re excited to partner with Protege to extend the reach and impact of our lab data infrastructure,” said Matt Martocci, Chief Commercial Officer at hc1. “We believe that lab results are the heartbeat of clinical care and improved patient outcomes, and by making this data available through our industry-leading hc1 IQTM platform, we’re supporting the next wave of innovation in personalized medicine and population-scale analytics.”